866-997-4948(US-Canada Toll Free)

Asthma - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Apr 2018

Category :

Pharmaceutical

No. of Pages : 592 Pages

Asthma - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H1 2018, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 40, 27, 1, 112, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Asthma - Overview 9
Asthma - Therapeutics Development 10
Asthma - Therapeutics Assessment 37
Asthma - Companies Involved in Therapeutics Development 55
Asthma - Drug Profiles 108
Asthma - Dormant Projects 524
Asthma - Discontinued Products 549
Asthma - Product Development Milestones 555
Appendix 566

List of Tables
Table 1: Number of Products under Development for Asthma, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Table 10: Number of Products under Development by Universities/Institutes, H1 2018
Table 11: Products under Development by Companies, H1 2018
Table 12: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 13: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 14: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 15: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 16: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 17: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Table 18: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Table 19: Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Table 20: Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Table 21: Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Table 22: Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Table 23: Products under Development by Universities/Institutes, H1 2018
Table 24: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Table 25: Number of Products by Stage and Target, H1 2018
Table 26: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Table 27: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Table 28: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Table 29: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Table 30: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
Table 31: Number of Products by Stage and Mechanism of Action, H1 2018
Table 32: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Table 33: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Table 34: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Table 35: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Table 36: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
Table 37: Number of Products by Stage and Route of Administration, H1 2018
Table 38: Number of Products by Stage and Molecule Type, H1 2018
Table 39: Asthma - Pipeline by 4D Pharma PLC, H1 2018
Table 40: Asthma - Pipeline by AB Science SA, H1 2018
Table 41: Asthma - Pipeline by AbbVie Inc, H1 2018
Table 42: Asthma - Pipeline by Abeome Corp, H1 2018
Table 43: Asthma - Pipeline by Accolade Pharmaceuticals LLC, H1 2018
Table 44: Asthma - Pipeline by Adamis Pharmaceuticals Corp, H1 2018
Table 45: Asthma - Pipeline by ALK-Abello AS, H1 2018
Table 46: Asthma - Pipeline by Allergan Plc, H1 2018
Table 47: Asthma - Pipeline by Allergopharma GmbH & Co KG, H1 2018
Table 48: Asthma - Pipeline by Almirall SA, H1 2018
Table 49: Asthma - Pipeline by Amgen Inc, H1 2018
Table 50: Asthma - Pipeline by Amphastar Pharmaceuticals Inc, H1 2018
Table 51: Asthma - Pipeline by AnaptysBio Inc, H1 2018
Table 52: Asthma - Pipeline by AnGes Inc, H1 2018
Table 53: Asthma - Pipeline by Antisense Therapeutics Ltd, H1 2018
Table 54: Asthma - Pipeline by Apollo Endosurgery Inc, H1 2018
Table 55: Asthma - Pipeline by ARA Healthcare Pvt Ltd, H1 2018
Table 56: Asthma - Pipeline by ASIT Biotech SA, H1 2018
Table 57: Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
Table 58: Asthma - Pipeline by Astellas Pharma Inc, H1 2018
Table 59: Asthma - Pipeline by AstraZeneca Plc, H1 2018
Table 60: Asthma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Table 61: Asthma - Pipeline by Biotec Pharmacon ASA, H1 2018
Table 62: Asthma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Table 63: Asthma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
Table 64: Asthma - Pipeline by Celon Pharma SA, H1 2018
Table 65: Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2018
Table 66: Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2018
Table 67: Asthma - Pipeline by Cognosci Inc, H1 2018
Table 68: Asthma - Pipeline by Crossject SA, H1 2018
Table 69: Asthma - Pipeline by CrystalGenomics Inc, H1 2018
Table 70: Asthma - Pipeline by CSL Ltd, H1 2018

List of Figures
Figure 1: Number of Products under Development for Asthma, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
Figure 4: Number of Products by Top 10 Targets, H1 2018
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *